Display options
Share it on

CMAJ Open. 2014 Oct 01;2(4):E306-17. doi: 10.9778/cmajo.20140012. eCollection 2014 Oct.

Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis.

CMAJ open

Leslea Peirson, James Douketis, Donna Ciliska, Donna Fitzpatrick-Lewis, Muhammad Usman Ali, Parminder Raina

Affiliations

  1. McMaster Evidence Review and Synthesis Centre, McMaster University Hamilton, Ont.
  2. Department of Medicine, McMaster University, Hamilton, Ont. ; St. Joseph's HealthCare, Hamilton, Ont.

PMID: 25485258 PMCID: PMC4251513 DOI: 10.9778/cmajo.20140012

Abstract

BACKGROUND: Obesity is a major public health issue. This review updates the evidence on the effectiveness of behavioural and pharmacologic treatments for overweight and obesity in adults.

METHODS: We updated the search conducted in a previous review. Randomized trials of primary-care-relevant behavioural (diet, exercise and lifestyle) and pharmacologic (orlistat and metformin) with or without behavioural treatments in overweight and obese adults were included if 12-month, postbaseline data were provided for weight outcomes. Studies reporting harms were included regardless of design. Data were extracted and pooled wherever possible for 5 weight outcomes, 6 secondary health outcomes and 4 adverse events categories.

RESULTS: We identified 68 studies, most consisted of short-term (≤ 12 mo) treatments using diet (n = 8), exercise (n = 4), diet and exercise (n = 10), lifestyle (n = 19), orlistat (n = 25) or metformin (n = 4). Compared with the control groups, intervention participants had a greater weight loss of -3.02 kg (95% confidence interval [CI] -3.52 to -2.52), a greater reduction in waist circumference of -2.78 cm (95% CI -3.34 to -2.22) and a greater reduction in body mass index of -1.11 kg/m(2) (95% CI -1.39 to -0.84). The relative risk for loss of ≥ 5% body weight was 1.77 (95% CI 1.58-1.99, [number needed to treat 5, 95% CI 4-7]), and the relative risk for loss of ≥ 10% body weight was 1.91 (95% CI 1.69-2.16, [number needed to treat 9, 95% CI 7-12]). Incidence of type 2 diabetes was lower among pre-diabetic intervention participants (relative risk 0.62 [95% CI 0.50-0.77], number needed to treat 17 [95% CI 13-29]). With prevalence rates for type 2 diabetes on the rise, weight loss coupled with a reduction in the incidence of type 2 diabetes could potentially have a significant benefit on population health and a possible reduction in need for drug treatments for glycemic control.

INTERPRETATION: There is moderate quality evidence that behavioural and pharmacologic plus behvioural, treatments for overweight and obesity in adults lead to clinically important reductions in weight and incidence of type 2 diabetes in pre-diabetic populations.

REGISTRATION: PROSPERO no. CRD42012002753.

References

  1. JAMA Intern Med. 2013 Jan 28;173(2):113-21 - PubMed
  2. JAMA. 1999 Jan 20;281(3):235-42 - PubMed
  3. BMC Public Health. 2009 Sep 16;9:342 - PubMed
  4. Eur J Clin Nutr. 2011 Nov;65(11):1256-62 - PubMed
  5. Obesity (Silver Spring). 2012 Aug;20(8):1628-38 - PubMed
  6. Am J Public Health. 2012 Feb;102(2):336-42 - PubMed
  7. Arch Intern Med. 2012 Mar 12;172(5):414-24 - PubMed
  8. BMJ Open. 2012 May 04;2(3):null - PubMed
  9. J Clin Pharm Ther. 2012 Apr;37(2):187-95 - PubMed
  10. Am J Public Health. 2010 Apr 1;100 Suppl 1:S232-9 - PubMed
  11. Diabetes Care. 2002 Jul;25(7):1123-8 - PubMed
  12. J Hypertens. 2005 Jun;23(6):1241-9 - PubMed
  13. Diabetes Care. 2002 Jun;25(6):1033-41 - PubMed
  14. Health Technol Assess. 2012 Aug;16(33):1-236, iii-iv - PubMed
  15. Diabetes Care. 1999 Apr;22(4):623-34 - PubMed
  16. Obesity (Silver Spring). 2011 Sep;19(9):1796-803 - PubMed
  17. J Hypertens. 2012 Jul;30(7):1430-9 - PubMed
  18. Clin Ther. 2003 Apr;25(4):1107-22 - PubMed
  19. Diabetes Obes Metab. 2005 May;7(3):254-62 - PubMed
  20. Obes Facts. 2010;3(2):93-100 - PubMed
  21. Arch Fam Med. 2000 Feb;9(2):160-7 - PubMed
  22. Int J Obes Relat Metab Disord. 2000 Mar;24(3):306-13 - PubMed
  23. Nutr Metab Cardiovasc Dis. 2011 Apr;21(4):261-8 - PubMed
  24. Diabetes Care. 1998 Aug;21(8):1288-94 - PubMed
  25. N Engl J Med. 2011 Nov 24;365(21):1969-79 - PubMed
  26. Public Health Nutr. 2011 Jun;14 (6):995-1000 - PubMed
  27. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
  28. Curr Med Res Opin. 2011 Jul;27(7):1431-8 - PubMed
  29. Diabetes Care. 2009 Jul;32(7):1143-6 - PubMed
  30. Arch Intern Med. 2012 Apr 9;172(7):565-74 - PubMed
  31. JAMA. 2003 Jan 1;289(1):76-9 - PubMed
  32. BMC Med Res Methodol. 2007 Feb 15;7:10 - PubMed
  33. J Cardiovasc Risk. 2003 Feb;10(1):31-40 - PubMed
  34. Diabet Med. 2005 May;22(5):612-8 - PubMed
  35. J Am Geriatr Soc. 2012 Sep;60(9):1655-62 - PubMed
  36. Public Health Nutr. 2009 Dec;12 (12 ):2382-91 - PubMed
  37. Exp Clin Endocrinol Diabetes. 2013 Jan;121(1):27-31 - PubMed
  38. Trials. 2012 Aug 28;13:152 - PubMed
  39. Arch Intern Med. 2002 Sep 9;162(16):1867-72 - PubMed
  40. Diabetes Care. 2004 Jan;27(1):155-61 - PubMed
  41. JAMA. 2005 Apr 20;293(15):1861-7 - PubMed
  42. JAMA. 1999 Oct 27;282(16):1530-8 - PubMed
  43. Fam Med. 1991 Jan;23(1):25-8 - PubMed
  44. Nutr Res. 2010 Dec;30(12 ):801-6 - PubMed
  45. Int J Behav Nutr Phys Act. 2010 Jan 06;7:1 - PubMed
  46. Am J Health Promot. 2013 Jan-Feb;27(3):191-9 - PubMed
  47. Lancet. 2011 Jul 9;378(9786):129-39 - PubMed
  48. BMC Public Health. 2011 Jan 24;11(1):49 - PubMed
  49. Asia Pac J Clin Nutr. 2012;21(1):22-34 - PubMed
  50. Nutr Metab Cardiovasc Dis. 2010 Oct;20(8):599-607 - PubMed
  51. Nutr Metab Cardiovasc Dis. 2010 Oct;20(8):608-17 - PubMed
  52. Blood Press. 1995 Nov;4(6):343-9 - PubMed
  53. Int J Clin Pract. 2002 Sep;56(7):494-9 - PubMed
  54. Cochrane Database Syst Rev. 2011 Sep 07;(9):CD008274 - PubMed
  55. Br J Nutr. 2011 Apr;105(7):1036-46 - PubMed
  56. N Engl J Med. 1991 Aug 15;325(7):461-6 - PubMed
  57. Obes Rev. 2012 Nov;13(11):1048-66 - PubMed
  58. Obes Res. 2000 Jan;8(1):49-61 - PubMed
  59. Obesity (Silver Spring). 2010 Jan;18(1):108-15 - PubMed
  60. Lancet. 1998 Jul 18;352(9123):167-72 - PubMed
  61. Can J Diabetes. 2013 Apr;37(2):128-34 - PubMed
  62. Ann Intern Med. 2001 Jan 2;134(1):1-11 - PubMed
  63. Diabetes Care. 2012 Feb;35(2):211-7 - PubMed
  64. J Obes. 2012;2012:985902 - PubMed
  65. Obesity (Silver Spring). 2010 Aug;18(8):1614-8 - PubMed
  66. Eur J Clin Pharmacol. 1998 Apr;54(2):125-32 - PubMed
  67. Obesity (Silver Spring). 2008 Nov;16(11):2462-7 - PubMed
  68. N Engl J Med. 2011 Nov 24;365(21):1959-68 - PubMed
  69. Arch Intern Med. 1993 Apr 12;153(7):849-58 - PubMed
  70. Diabetes Obes Metab. 2002 Nov;4(6):415-23 - PubMed
  71. Exp Clin Endocrinol Diabetes. 2012 Sep;120(8):445-50 - PubMed
  72. J Hypertens. 2002 Nov;20(11):2257-67 - PubMed
  73. Ann Behav Med. 2011 Dec;42(3):391-401 - PubMed
  74. Int J Obes Relat Metab Disord. 2001 Nov;25(11):1713-21 - PubMed
  75. J Intern Med. 2000 Sep;248(3):245-54 - PubMed
  76. Int J Obes Relat Metab Disord. 2003 May;27(5):591-7 - PubMed
  77. N Engl J Med. 1988 Nov 3;319(18):1173-9 - PubMed
  78. Diabetes Care. 1996 Sep;19(9):920-6 - PubMed
  79. Obes Rev. 2011 May;12(5):e412-25 - PubMed
  80. Arch Intern Med. 2008 Jan 28;168(2):141-6 - PubMed
  81. Med J Aust. 2001 Jun 4;174(11):590-2 - PubMed
  82. JAMA. 1985 Feb 1;253(5):657-64 - PubMed

Publication Types